论文部分内容阅读
由Celgene公司开发的pomalidomide(商品名:Pomalyst)于2013年2月8日获美国FDA批准,用于治疗复发性或难治性[经至少2种抗肿瘤药物(包括来那度胺和硼替佐米)治疗但不产生应答或末次治疗后60 d内发生恶化]的多发性骨髓瘤。
Pomalidomide (trade name: Pomalyst) developed by Celgene was approved by the U.S. FDA on February 8, 2013 for the treatment of recurrent or refractory [at least 2 antineoplastic agents including lenalidomide and bortezomib M) but did not respond or worsen within 60 days after the last treatment].